"Cancer care has changed dramatically in the last 50 years. Screening, surgery, targeted therapies, immunotherapy, and precision medicine have improved the outlook for many once-intractable diseases. Glioblastoma, an aggressive brain cancer, is a notable exception."

"Survival for glioblastoma multiforme (GBM) has improved only marginally over the past several decades, in part because traditional pre-clinical models fail to replicate how GBM infiltrates the human brain. To address this issue, Dr. Howard Fine has spent the past 15 years developing the GLICO (Glioma Cerebral Organoid) model, which creates mini brains derived from patients’ stem cells and co-cultures them with their glioma cells to accurately mimic the diffuse nature of GBM in a patient-specific way."